Bederra Corporation Reports First Quarter Financial Statements

HOUSTON, TX-- Bederra Corporation (PINKSHEETS: BEDA), a Houston, Texas-based diversified medical services provider, recently published its first quarter results on www.pinksheets.com. For the quarter ending March 31, 2009, the company grossed revenues of $737,602.00. While on a cash basis the first quarter financial statements show an operating loss of $62,925.00, the tremendous early success of the company's recently launched medical clinic -- the Reliant Medical Group Clinic -- the company is expected to be profitable on an accrual basis by the end of the second fiscal quarter, and cash flow positive by August of this year. The company's balance sheet for the first quarter reports $737,550.00 in total assets after depreciation, including first quarter receivables of $258,693.00.

Furthermore, management has maintained its positive outlook regarding the company's financials despite the economic downturn which management believes has left many patients reluctant or unable to pay deductibles and insurance premiums. With the launch of the Reliant Medical Group Clinic and the addition of specialized equipment including a nuclear camera, management expects the company to show a profit overall for its full fiscal year ending in December.

Additionally, the company is in the process of changing transfer agents which should result in the upgrading of the company's current "Pink Sheets Limited Information" categorization to a "Pink Sheets Current Issuer" listing. Management anticipates the change to a "Current Issuer" listing to be completed before the end of July.

About Bederra Corp.

http://www.bederra.com

Bederra Corporation, through its wholly owned subsidiaries Lumar Imaging, Inc., Reliant Medical Group and Diagnos, Inc; provides multiple modality diagnostic medical imaging services to the greater Houston area and the world famous Texas Medical Center. The Company's business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

---

Add this page to your favorite Social Bookmarking websites